5 ms·

This destroys all your B-cells in your body, right? That means the B-cells aren't available for normal operation any more, right? I guess it's better to be immu

by est31 5y ago

This destroys all your B-cells in your body, right? That means the B-cells aren't available for normal operation any more, right? I guess it's better to be immuno compromised than dead...

inter_netuser 5y ago
They are regenerated in 2-3 months.
- mft_ 5y ago
  CAR-Ts can persist ("engraft") and cause long-term supression of the normal B-cells, and happily the malignant B-cells also.
  - inter_netuser 5y ago
    how common is that?
netizen-936824 5y ago
That's likely the reason its referred to as "last resort" Having a working immune system won't do you any good if you're dead
- mft_ 5y ago
  They aren't - that's just journalistic hyperbole, relating to the very first patients. CAR-Ts are now being tested in much earlier lines of therapy.
drocer88 5y ago
Yes ( well, maybe not "all" ). For example, Yescarta® is an FDA approved CAR T-cell therapy for patients with refractory b-cell lymphoma. From https://www.gilead.com/-/media/files/pdfs/medicines/other/yescarta/yescarta.pdf https://www.gilead.com/-/media/files/pdfs/medicines/other/ye... : "Before you get YESCARTA, you will get 3 days of chemotherapy to prepare your body". This chemotherapay is "lymphodepleting" ( https://www.yescartahcp.com/large-b-cell-lymphoma https://www.yescartahcp.com/large-b-cell-lymphoma ). This chemotherapy decreases the number of T cells. Gilead just reported a 5 year follow up on their therapy : https://www.gilead.com/news-and-press/press-room/press-releases/2021/12/yescarta-is-first-car-t-cell-therapy-to-report-five-year-survival-data-from-pivotal-study-showing-durable-long-term-survival-in-patients-with-refract https://www.gilead.com/news-and-press/press-room/press-relea... . " 92% of Patients Alive at Five Years Have Needed No Additional Cancer Treatments; Data Suggestive of a Potential Cure for These Patients "
doctoring 5y ago
Yes. B-cells (normally) make antibodies, so these patients usually receive regular infusions of antibodies by IV (which come from blood donations) to keep their circulating antibody levels up.
spopejoy 5y ago
> This destroys all your B-cells in your body, right? If you have DLBCL/FL, all treatments go after B-cells. CAR-T is just better at doing that and nothing else.

by est31 5y ago

This destroys all your B-cells in your body, right? That means the B-cells aren't available for normal operation any more, right? I guess it's better to be immuno compromised than dead...

inter_netuser 5y ago

They are regenerated in 2-3 months.

mft_ 5y ago
CAR-Ts can persist ("engraft") and cause long-term supression of the normal B-cells, and happily the malignant B-cells also.
- inter_netuser 5y ago
  how common is that?

netizen-936824 5y ago

That's likely the reason its referred to as "last resort" Having a working immune system won't do you any good if you're dead

mft_ 5y ago
They aren't - that's just journalistic hyperbole, relating to the very first patients. CAR-Ts are now being tested in much earlier lines of therapy.

drocer88 5y ago

Yes ( well, maybe not "all" ). For example, Yescarta® is an FDA approved CAR T-cell therapy for patients with refractory b-cell lymphoma. From https://www.gilead.com/-/media/files/pdfs/medicines/other/yescarta/yescarta.pdf https://www.gilead.com/-/media/files/pdfs/medicines/other/ye... : "Before you get YESCARTA, you will get 3 days of chemotherapy to prepare your body". This chemotherapay is "lymphodepleting" ( https://www.yescartahcp.com/large-b-cell-lymphoma https://www.yescartahcp.com/large-b-cell-lymphoma ). This chemotherapy decreases the number of T cells. Gilead just reported a 5 year follow up on their therapy : https://www.gilead.com/news-and-press/press-room/press-releases/2021/12/yescarta-is-first-car-t-cell-therapy-to-report-five-year-survival-data-from-pivotal-study-showing-durable-long-term-survival-in-patients-with-refract https://www.gilead.com/news-and-press/press-room/press-relea... . " 92% of Patients Alive at Five Years Have Needed No Additional Cancer Treatments; Data Suggestive of a Potential Cure for These Patients "

doctoring 5y ago

Yes. B-cells (normally) make antibodies, so these patients usually receive regular infusions of antibodies by IV (which come from blood donations) to keep their circulating antibody levels up.

spopejoy 5y ago

> This destroys all your B-cells in your body, right? If you have DLBCL/FL, all treatments go after B-cells. CAR-T is just better at doing that and nothing else.